aXichem AB (publ), publishes an English translation of the company's Annual Report 2025.
The Annual Report and Consolidated Financial Statements for aXichem AB (publ) 2025 are available on the company's website at https://www.axichem.com/arsstamma-2026/
The information was submitted, through the agency of the contact person, for publication on June 10, 2026, at 09:00 CET.
Company contact:
Torsten Helsing, CEO, aXichem AB
Telephone: +46 706 863 355. E-mail: torsten.helsing@axichem.com
About aXichem
aXichem develops, patents, and markets natural analogue industrial chemicals, i.e., synthetically produced substances that have similar and comparable properties to natural substances. The company's first product is phenylcapsaicin, which the company commercializes under two brands, aXiphen® and aXivite®, as an ingredient in animal feed and dietary supplements, respectively. The business is divided into three market areas with different applications for phenylcapsaicin: as an ingredient in feed for poultry, such as chicken and turkey, and for ruminants; as an ingredient in food supplements for gut health, weight control and sports and exercise; and as an ingredient in food supplements for the bio-enhancement of curcumin and melatonin. aXichem is listed on the Nasdaq First North Growth Market. Certified advisor for aXichem is Västra Hamnen Corporate Finance AB. More information is available at www.axichem.com.